Drug intelligence / Profile preview

SGI-AXL-277

Development stage: Preclinical
Lead developer: Supergene
Modality: Small Molecules

Overview

SGI-AXL-277 is a small molecule inhibitor of the AXL receptor tyrosine kinase, featuring a pyrrolopyrimidine scaffold. It was developed by SuperGen (which later merged with Astex Pharmaceuticals). AXL is a member of the TAM (Tyro3, Axl, Mer) receptor tyrosine kinase family and is frequently overexpressed in various malignancies, where it promotes tumor cell survival, epithelial-to-mesenchymal transition (EMT), and resistance to chemotherapy and targeted agents. SGI-AXL-277 was reported to be in the lead optimization and biological testing phases of preclinical development around 2011, specifically targeting solid tumors. However, there has been limited information regarding its clinical progression or current status in the pipeline since that time.

Targets

AXL (AXL receptor tyrosine kinase)

Beyond the preview

Go deeper on SGI-AXL-277.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGI-AXL-277.

Explore the full profile